Page last updated: 2024-12-06

cephapirin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cephapirin: Cephalosporin antibiotic, partly plasma-bound, that is effective against gram-negative and gram-positive organisms. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cephapirin : A cephalosporin with acetoxymethyl and 2(pyridin-4-ylsulfanyl)acetamido substituents at positions 3 and 7, respectively, of the cephem skeleton. It is used (as its sodium salt) as an antibiotic, being effective against gram-negative and gram-positive organisms. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID30699
CHEMBL ID1599
CHEBI ID554446
SCHEMBL ID3205
MeSH IDM0003832

Synonyms (94)

Synonym
DIVK1C_000042
KBIO1_000042
(6r,7r)-3-[(acetyloxy)methyl]-8-oxo-7-{[(pyridin-4-ylthio)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SPECTRUM_000112
BSPBIO_001965
LOPAC0_000279
PRESTWICK2_000851
D07636
cefapirin (ban)
metricure (tn)
cephapirine
(6r,7r)-3-(acetoxymethyl)-8-oxo-7-[[2-(4-pyridylsulfanyl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
antibiotic bl-p1322
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-8-oxo-7-[[(4-pyridinylthio)acetyl]amino]-, (6r,7r)-
cefapirin
cefa
cefa -ak
cefaprin sodium
SPECTRUM5_000671
IDI1_000042
21593-23-7
C06896
cephapirin
cefaprin
DB01139
(6r,7r)-3-(acetoxymethyl)-8-oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cepr
cephalosporanic acid, 7-(2-(4-pyridylthio)acetamido)-
3-(hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamidol-5-thia-1-azabicyclo(4.2.0)oct-2-en-2carbonsaeure acetat
7-(2-(4-pyridylthio)acetamido)cephalosporanic acid
brn 1095157
cefapirine [inn-french]
hsdb 3215
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-8-oxo-7-(((4-pyridinylthio)acetyl)amino)-, (6r-trans)-
cefapirin [inn:ban]
(6r,7r)-3-(acetoxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure
cefapirina [inn-spanish]
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-, acetate (ester)
einecs 244-466-5
cefapirinum [inn-latin]
KBIO2_005688
KBIO3_001185
KBIO2_003120
KBIOGR_000740
KBIOSS_000552
KBIO2_000552
SPBIO_000086
PRESTWICK1_000851
SPBIO_002782
NINDS_000042
SPECTRUM3_000333
SPECTRUM4_000270
SPECTRUM2_000103
PRESTWICK0_000851
CHEMBL1599
(6r,7r)-3-acetoxymethyl-7-[(pyridin-4-ylsulfanyl)acetamido]-3,4-didehydrocepham-4-carboxylic acid
CHEBI:554446 ,
(6r,7r)-3-(acetyloxymethyl)-8-oxo-7-[(2-pyridin-4-ylsulfanylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cefapirinum
cefapirine
cefapirina
unii-89b59h32vn
89b59h32vn ,
cefa-lak
bdbm50370592
cefapirin [who-dd]
7-(.alpha.-(4-pyridylthio)acetamido)cephalosporanic acid
cephapirin [vandf]
cephapirin [mi]
cefapirin [hsdb]
(6r,7r)-3-(hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate acetate (ester)
cefapirin [inn]
EPITOPE ID:116226
AKOS015896499
SCHEMBL3205
UQLLWWBDSUHNEB-CZUORRHYSA-N
DTXSID9022784 ,
(6r,7r)-3-[(acetyloxy)methyl]-8-oxo-7-[2-(pyridin-4-ylsulfanyl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
J-014163
SBI-0050267.P004
(6r,7r)-3-(acetoxymethyl)-8-oxo-7-(2-(pyridin-4-ylthio)acetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Q549803
gtpl12191
CS-0017478
HY-A0153
(6r,7r)-3-(acetoxymethyl)-8-oxo-7-(2-(pyridin-4-ylthio)acetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid
cefapirine (inn-french)
(6r,7r)-3-acetoxymethyl-7-((pyridin-4-ylsulfanyl)acetamido)-3,4-didehydrocepham-4-carboxylic acid
7-(alpha-(4-pyridylthio)acetamido)cephalosporanic acid
cefapirina (inn-spanish)
dtxcid602784
(6r,7r)-3-(acetoxymethyl)-8-oxo-7-(((pyridin-4-ylsulfanyl)acetyl)amino)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
cefapirinum (inn-latin)
EN300-25916814

Research Excerpts

Actions

ExcerptReferenceRelevance
"Cephapirin did not inhibit particulate D-alanine carboxypeptidase activity and presumably did not bind covalently to this penicillin-binding protein."( The formation of functional penicillin-binding proteins.
Hamilton, TE; Lawrence, PJ, 1975
)
0.98

Treatment

Cephapirin treatment had also no positive effect on other reproductive performance measures, i.e., the percentage of pregnant cows 200 days after enrollment. Treatment with cephaprin was associated with a significant improvement of the FSCR in PVD+ cows.

ExcerptReferenceRelevance
"Cephapirin treatment had also no positive effect on other reproductive performance measures, i.e, the percentage of pregnant cows 200 days after enrollment (HE: 64.1%, CON: 73.6%, and MET: 73.6%) or the mean interval from enrollment to conception (HE: 25.4 days, CON: 30.0 days, and MET: 29.7 days)."( Field trial on the post-insemination intrauterine treatment of dairy cows with mild endometritis with cephapirin.
Ballas, P; Baumgartner, W; Drillich, M; Ehling-Schulz, M; Iwersen, M; Reinländer, U; Schlegl, R; Wagener, K, 2020
)
1.49
"Cephapirin treatment was also associated with an increased first-service reproductive performance in cows affected simultaneously by both PVD and ENDO-CYTO (no treatment: 8.7%; treatment: 23.4%)."( Randomized clinical trial of intrauterine cephapirin infusion in dairy cows for the treatment of purulent vaginal discharge and cytological endometritis.
Denis-Robichaud, J; Dubuc, J, 2015
)
1.4
"Treatment with cephapirin was associated with a significant improvement of the FSCR in PVD+ cows (PVD+ CEPH: 36 ± 5%, PVD+ CONT: 23 ± 5%; P < 0.05), although it did not produce a considerable clinical cure based on the second examination."( Effectiveness of intrauterine treatment with cephapirin in dairy cows with purulent vaginal discharge.
Bouchard, E; DesCôteaux, L; Lefebvre, RC; Tison, N, 2017
)
1.05

Toxicity

ExcerptReferenceRelevance
" These findings, together with the results of other reports, suggest that CEPR is a safe and useful drug in the treatment of infection as compared with CET."( [Comparison of side effects of intravenous cephapirin and cephalothin with special reference to the incidence of phlebitis].
Konno, K; Oizumi, K; Watanabe, A, 1983
)
0.53
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32

Pharmacokinetics

ExcerptReferenceRelevance
"A review is given on the pharmacokinetic characteristics of some cephalosporin antibiotics."( On the pharmacokinetics of cephalosporin antibiotics.
Andersson, KE, 1978
)
0.26
" Pharmacokinetic analyses of the concentrations of cephapirin and desacetylcephapirin in plasma and urine reveal that the rate and extent of deacetylation decreases from rodents to dogs to humans."( Comparative pharmacokinetics and metabolism of cephapirin in laboratory animals and humans.
Cabana, BE; Hottendorf, GH; van Harken, DR, 1976
)
0.76
" The serum concentration curves appeared to decline bi-exponentially, suggesting that a two-compartment model was most applicable for pharmacokinetic analysis; accordingly, the t((1/2)) of cefamandole was significantly longer when the serum peak was omitted from the analysis (0."( Comparative pharmacokinetics of cefamandole, cephapirin, and cephalothin in healthy subjects and effect of repeated dosing.
Barza, M; Berger, S; Ernst, EC; Melethil, S, 1976
)
0.52
" Pharmacokinetic parameters were calculated by one-compartment model and two-compartment model."( [Pharmacokinetics of cephapirin sodium during intravenous infusion].
Imoto, T, 1983
)
0.58
" The greater the surface area in relation to the volume of the extravascular space, the more closely its kinetics mimicked those of the intravascular space-that is, the higher the absolute peak concentration of drug achieved in the extravascular space, the greater the peak-to-trough fluctuation and the more quickly the peak concentration of drug was reached."( Effect of the ratio of surface area to volume on the penetration of antibiotics in to extravascular spaces in an in vitro model.
Fasching, CE; Gerding, DN; Peterson, LR; Van Etta, LL, 1982
)
0.26
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Data were fitted using 1- and 2-compartment pharmacokinetic models, as well as a noncompartmental model."( Effect of milking frequency and dosing interval on the pharmacokinetics of cephapirin after intramammary infusion in lactating dairy cows.
Constable, PD; Lantz, RK; Morin, DE; Stockler, RM, 2009
)
0.58
" A non-compartmental model was applied to data to obtain pharmacokinetic results."( Pharmacokinetics in foremilk and antimicrobial activity of cephapirin following intramammary administration in healthy and Staphylococcus aureus-infected cows.
Bronzo, V; Cagnardi, P; Carli, S; Ferraresi, C; Locatelli, C; Villa, R; Zonca, A, 2014
)
0.65
"4) µg/mL), but the elimination half-life was longer in the infected (4."( Pharmacokinetics in foremilk and antimicrobial activity of cephapirin following intramammary administration in healthy and Staphylococcus aureus-infected cows.
Bronzo, V; Cagnardi, P; Carli, S; Ferraresi, C; Locatelli, C; Villa, R; Zonca, A, 2014
)
0.65

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of the drug was greater than or equal to 95% after IM injection."( Pharmacokinetics and body fluid and endometrial concentrations of cephapirin in mares.
Brown, MP; Gronwall, RR; Houston, AE, 1986
)
0.51
"The utilization of the membrane transport protein PEPT1 as a drug delivery system is a promising strategy to enhance the oral bioavailability of drugs."( Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I, 2005
)
0.33

Dosage Studied

Six calves with suppurative arthritis were given a single IM injection of sodium cephapirin at a dosage of 10 mg/kg of body weight. Repeated dosing had no effect on the peak serum levels, half-life, serum clearance, or apparent volume of distribution. Peak serum levels were significantly lower after the sixteenth than after the first dose.

ExcerptRelevanceReference
"A simple and specific method for the quantitative determination of cephapirin, a cephalosporin antibacterial, in finished bulk and dosage forms is reported."( Spectrophotometric determination of cephapirin, a cephalosporin antibacterial.
Bodnar, JE; Evans, WG; Mays, DL, 1977
)
0.77
" Repeated dosing had no effect on the peak serum levels, half-life, serum clearance, or apparent volume of distribution with one exception: peak serum levels of cephapirin were significantly lower after the sixteenth than after the first dose."( Comparative pharmacokinetics of cefamandole, cephapirin, and cephalothin in healthy subjects and effect of repeated dosing.
Barza, M; Berger, S; Ernst, EC; Melethil, S, 1976
)
0.71
" No such abnormalities were evident after infusion of cefazolin or cephapirin at a maximal dosage of 200 mg/kg per day."( Influence of cephalosporin antibiotics on blood coagulation and platelet function.
Alfrey, CP; Bradshaw, MW; Brown, CH; Natelson, EA; Williams, TW, 1976
)
0.49
"Six calves with suppurative arthritis were given a single IM injection of sodium cephapirin at a dosage of 10 mg/kg of body weight."( Pharmacokinetics and synovial fluid concentrations of cephapirin in calves with suppurative arthritis.
Brown, MP; Gronwall, RR; Houston, AE; Pattio, N; Poulos, PW, 1991
)
0.76
" at a dosage of 20 mg/kg for 5 days."( Characterization of a soft-tissue infection model in the horse and its response to intravenous cephapirin administration.
Beadle, RE; Clarke, CR; Corstvet, RE; Guthrie, AJ; McClure, JR; Nobles, DD; Pawlusiow, J; Short, CR, 1989
)
0.5
" Each mare was then given 4 consecutive IM injections of sodium cephapirin (400 mg/ml) at a dosage level of 20 mg/kg."( Pharmacokinetics and body fluid and endometrial concentrations of cephapirin in mares.
Brown, MP; Gronwall, RR; Houston, AE, 1986
)
0.75
" Recommendations for dosage are given."( Pharmacokinetics of cefapirin in patients with normal and impaired renal functions.
Bergan, T; Brodwall, EK; Orjavik, O, 1981
)
0.26
"] serum concentrations to establish a proper multiple dosage regimen were 52."( Disposition kinetics and bioavailability of piperacillin and cephapirin in mares.
el-Komy, AA, 1995
)
0.53
"Liquid chromatography-ion trap tandem mass spectrometry (LC-MS/MS) with electrospray ionization was used to identify cephapirin metabolites and degradants in milk from cows dosed with cephapirin."( Identification of cephapirin metabolites and degradants in bovine milk by electrospray ionization--ion trap tandem mass spectrometry.
Heller, DN; Kaplan, DA; Rummel, NG; von Bredow , J, 2000
)
0.85
" The dose-response curves were bell shaped, indicating toxic effects for the sensor strain at high concentrations of beta-lactams."( A luminescent Escherichia coli biosensor for the high throughput detection of beta-lactams.
Karp, MT; Kurittu, JS; Valtonen, SJ, 2002
)
0.31
"The objective was to determine the effect of milking frequency and dosing interval on pharmacokinetics of cephapirin after intramammary infusion."( Effect of milking frequency and dosing interval on the pharmacokinetics of cephapirin after intramammary infusion in lactating dairy cows.
Constable, PD; Lantz, RK; Morin, DE; Stockler, RM, 2009
)
0.8
" Results of the part I (internal) and part II (independent laboratory) dose-response studies employing spiked samples were in close agreement."( Validation study of the BetaStar plus lateral flow assay for detection of beta-lactam antibiotics in milk.
Abouzied, M; Ankrapp, D; Driksna, D; Klein, F; Mozola, M; Rice, J; Sarzynski, M; Walsh, A; Walsh, C,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
cephalosporinA class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 15 member 1Homo sapiens (human)Ki10,000.00000.18003.39339.8000AID238858; AID681115
Solute carrier family 15 member 2Rattus norvegicus (Norway rat)Ki10,000.00003.00006.47788.5000AID681114
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID399203Antibacterial activity against methicillin-resistant Staphylococcus aureus after 20 hrs2004Journal of natural products, Jan, Volume: 67, Issue:1
A pair of new C-21 steroidal glycoside epimers from the roots of Cynanchum paniculatum.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID238858Binding affinity against membrane transport protein PEPT1 in human Caco-2 cells2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID409953Inhibition of mouse liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID378072Antimicrobial activity against methicillin-resistant Staphylococcus aureus COL at 20 ug/disk after 24 hrs by disk diffusion method2006Journal of natural products, Aug, Volume: 69, Issue:8
Chemical constituents from the peels of Citrus sudachi.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID681114TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in SKPT cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID681115TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in Caco-2 cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID378074Antimicrobial activity against methicillin-resistant Staphylococcus aureus 5 at 20 ug/disk after 24 hrs by disk diffusion method2006Journal of natural products, Aug, Volume: 69, Issue:8
Chemical constituents from the peels of Citrus sudachi.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (381)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990270 (70.87)18.7374
1990's36 (9.45)18.2507
2000's29 (7.61)29.6817
2010's35 (9.19)24.3611
2020's11 (2.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.21 (24.57)
Research Supply Index6.13 (2.92)
Research Growth Index4.44 (4.65)
Search Engine Demand Index65.75 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (43.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials42 (10.05%)5.53%
Reviews11 (2.63%)6.00%
Case Studies12 (2.87%)4.05%
Observational0 (0.00%)0.25%
Other353 (84.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]